Age-related macular degeneration (AMD) is the primary cause of severe vision loss in old age patients in developed countries and exudative (wet) AMD is characterized by choroidal neovascularization (CNV).
Age-related macular degeneration (AMD) is the primary cause of severe vision loss in old age patients in developed countries and exudative (wet) AMD is characterized by choroidal neovascularization (CNV). 1, 2) Surgical therapy or photocoagulation therapy has been performed to treat CNV, [3] [4] [5] [6] [7] [8] but these therapies affect not only the CNV itself but also the healthy retina. Therefore drug therapy for CNV with minimal damage to the healthy retina is under investigation and many anti-angiogenic agents have been evaluated. [9] [10] [11] [12] [13] [14] [15] [16] Angiogenesis is an important process by which new blood vessels are formed from preexisting microvessels in many diseases such as cancer, diabetic retinopathy, and exudative AMD. 17) It has been reported that anecortave acetate, an angiostatic steroid, is clinically efficacious for improving vision in patients with exudative AMD. 14) Betamethasone is a corticosteroid with anti-inflammatory and immunosuppressive abilities, and it has been reported that betamethasone shows anti-angiogenic activities in some experimental studies. [18] [19] [20] We synthesized 9a-fluoromedroxyprogesterone acetate (FMPA) in order to explore a more potent anti-angiogenic agent than medroxyprogesterone acetate (MPA), 21) which has been widely used as a therapeutic agent for breast and endometrium cancers. FMPA showed 100-times greater antiangiogenic activity than MPA in the chorioallantoic membrane (CAM) assay system 21) and showed a 7-fold stronger anti-angiogenic effect than MPA in the rabbit corneal assay system. 22) FMPA inhibited the activity of plasminogen activator (PA), an important protease playing an essential role in the process of angiogenesis, in bovine endothelial cells. 23) In the mouse dorsal air sac method, FMPA inhibited the mouse sarcoma 180 cell-induced angiogenesis by oral administration. 23) These results indicate that FMPA may be useful for the treatment of diseases associated with angiogenesis. However, there has been no study of the effect of FMPA on CNV. Therefore, in this study, we examined the effect of FMPA on laser-induced CNV in rats, and also the effects of anecortave acetate and betamethasone as positive controls on laser-induced CNV in rats. In addition, we also examined the effect of FMPA on the retinal function by electro retinogram (ERG) to confirm whether or not FMPA had retinal toxicity.
MATERIALS AND METHODS
Animals Male 8-week-old Brown Norway (BN) rats from Charles River Japan were used. These rats were housed under standard pathogen-free conditions in constant periods of 12-h light/dark (23°C) and were allowed access to food and water ad libitum. All experiments proceeded in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.
Chemicals FMPA was synthesized in our laboratory as reported previously.
21) The structure of FMPA is shown in Fig. 1 . Anecortave acetate was synthesized in our laboratory. Evaluation of the Effect of FMPA on Experimental CNV The rats were anesthetized for all procedures with intramuscular injection of a 1 ml/kg mixture (7 : 1) of ketamine hydrochloride (Ketalar; Sankyo, Tokyo, Japan) and xylazine hydrochloride (Celactal; Bayer, Tokyo, Japan). The pupil was dilated with 0.5% tropicamide and 0.5% phenylephrine hydrochloride (Mydrine P, Santen Pharmaceutical, Osaka, Japan) eye drops. Crypton laser (MC-7000L, Nidek Co., Ltd., Osaka, Japan) was applied to the fundus (spot size 100 mm, power 100 mV, exposure time 0.1 s) in rats. Eight laser photocoagulations were performed in each eye between the major retinal vessels of the superior retina (day 0). Fundus photograph in rat eye after eight laser photocoagulations (day 0) is shown in Fig. 2A . Four rats in each group were injected subconjunctivally with FMPA (100, 300, 1000, 3000 mg/eye), anecortave acetate (1000 mg/eye), betamethasone (100 mg/ eye) or vehicle (0.4% Tween 80/2.6% glycerol solution, 50 ml/eye) once just after the photocoagulation on day 0. On day 14, 10% fluorescein (0.1 ml/rat) was injected intravenously and fundus fluorescein angiography (FAG) was performed to evaluate CNV formation using the fundus camera (Pro III, Kowa Company, Ltd., Japan). Fundus photograph of FAG in rat eye on day 14 after eight laser photocoagulations is shown in Fig. 2B . CNV formation was classified on the basis of a fluorescein angiogram at the laser photocoagulation spot as follows: negative, no fluorescein leakage; positive, fluorescein leakage. The incidence of CNV was calculated in each eye as the percentage of CNV positive spots to total laser photocoagulation spots (8 spots). All rats were weighed before the experiment (day 0) and once a week during the experiment (day 7, 14) .
Evaluation of the Effect of FMPA on Retinal Function On the day after evaluation of CNV formation by FAG (day 15), the rats underwent dark adaptation by housing in a dark room for 1 h. After dark adaptation, under dim red light illumination, the rats were anesthetized with intramuscular injection of a 1 ml/kg mixture (7 : 1) of ketamine hydrochloride and xylazine hydrochloride, and the pupil was dilated with 0.5% tropicamide and 0.5% phenylephrine hydrochloride eye drops. The rats under anesthesia were applied with 0.4% oxybuprocaine hydrochloride eye drop and an LED electrode was placed on the eye. An earth electrode was placed at the tail and an indifferent electrode was placed in the nose. The ERG was recorded in response to a light stimulus (electroluminescence luminance; 3000 cd/m 2 (500 mW), time; 150 ms). The amplitudes of a-wave and b-wave were measured using SYNAX ER1100 (NEC, Japan) and the ratio of the amplitude of b-wave to the amplitude of a-wave was calculated in each eye.
Statistical Analysis Data are expressed as the meanϮ S.E. Statistical analysis was performed with Dunnett's multiple comparison test or the Student's t-test. p<0.05 was considered statistically significant.
RESULTS
Effect of FMPA on Experimental CNV The incidence of CNV was expressed as percentage of the vehicle injected group and the incidence of CNV in each group is shown in Fig. 3 . In a rat model of CNV, subconjunctival injection of FMPA at doses of 300, 1000 and 3000 mg/eye dose-dependently inhibited the incidence of CNV formation. The incidences of CNV at doses of 1000 and 3000 mg/eye of FMPA were 62.2Ϯ6.7% and 48.9Ϯ6.5%, respectively, and significant differences were observed as compared with the vehicle injected group (p<0.01). The incidences of CNV at a dose of 1000 mg/eye of anecortave acetate and at a dose of 100 mg/eye of betamethasone were 73.3Ϯ6.2% and 26.7Ϯ7.5%, respectively, and significant differences were observed as compared with the vehicle injected group ( p<0.01). There was no statistical difference between the incidences of CNV in FMPA injected group (1000 mg/eye) and that in anecortave acetate injected group (1000 mg/eye). 
Effect of FMPA on Retinal Function
The ratio of the amplitude of b-wave to a-wave in ERG in each group is shown in Fig. 4 . There was no statistical difference between the ratio of the amplitude of b-wave to a-wave in each FMPA injected group and that in the vehicle injected group. Therefore, FMPA did not affect the retinal function at doses of 100-3000 mg/eye by ERG in rats. The ratio of the amplitude of b-wave to a-wave in both anecortave acetate injected group and betamethasone injected group were not significantly different from that in the vehicle injected group, thus anecortave acetate (1000 mg/eye) and betamethasone (100 mg/eye) did not affect the retinal function.
Effect of FMPA on Body Weight There were no statistical differences between the changes of body weight in FMPA injected groups (100, 300, 1000 mg/eye) and that in the vehicle injected group (Fig. 5 ). There were no statistical differences between the changes of body weight in anecortave acetate injected group (1000 mg/eye) and that in the vehicle injected group (Fig. 5) . In the FMPA injected group at a dose of 3000 mg/eye and betamethasone injected group at a dose of 100 mg/eye, changes of body weight were significantly inhibited as compared with the vehicle treated group (p<0.01).
DISCUSSION
AMD is a retinal disease causing severe and irreversible vision loss, and is a major cause of blindness in elderly patients. 1, 2) AMD is classified into the exudative (wet) form and the atrophic (dry) form; the exudative form destroys vision more quickly than the atrophic form. In the exudative form of AMD, CNV extends through Bruch's membrane and into the subretinal space and subretinal pigment epithelium. Some therapies such as surgical therapy and photocoaguration therapy have been used to treat CNV, [3] [4] [5] [6] [7] [8] but these therapies affect the normal chorioretinal tissue. Recently, several anti-angiogenic agents, including TNP-470, irsogladine and anecortave acetate, have been investigated to verify their potential for clinical use as a new drug for CNV. 9, 11, 14, [24] [25] [26] FMPA is a synthetic analog of MPA. It has been widely used as a therapeutic agent for breast and endometrium cancers without unacceptable side effects, and synthesized in order to enhance its anti-tumor and anti-angiogenic activities by fluorinating MPA. 21) FMPA has anti-tumor activity against rat mammary cancer and its activity is greater than that of the parent compound, MPA. 22) In addition, FMPA has shown greater anti-angiogenic activity than MPA in some assay systems such as the CAM assay system 21) and rabbit corneal assay system. 22) These findings suggest that FMPA would become a potential candidate drug for treatment of CNV. However, there has been no study of the effect of FMPA on CNV. Therefore, in this study, we investigated the effect of FMPA on laser-induced CNV in rats. The laser-induced CNV model in rats has been widely used for study of CNV. [10] [11] [12] [24] [25] [26] [27] The essential process of CNV formation in this model, including the break-up of the basement membrane, the migration and proliferation of vascular endothelial cells and the tubular formation, is similar to the naturally-occurring process. In this study, FMPA inhibited the incidence of CNV formation by subconjunctival injection, and it was thus thought that FMPA might be useful drug for treating CNV.
PA is an important protease playing an essential role in the process of angiogenesis. 28) Irsogladine, an anti-gastric ulcer agent, inhibits the synthesis of PA and angiogenesis, 29, 30) and also inhibits the development of experimental laser-induced CNV in rats.
11) FMPA inhibited the activity of PA in bovine endothelial cells and this activity was almost the same as that of MPA reported by Ashino-Fuse et al. 31) So, one of the mechanisms of anti-angiogenic action of FMPA was considered to be the suppression of PA activity. However, FMPA may have another mechanism different from that of MPA, because FMPA showed greater anti-angiogenic activity than MPA. FMPA inhibited the rat mammary tumor-induced angiogenesis in the rabbit corneal assay 22) and the rat mammary tumor was induced by 7,12-dimethylbenz[a]anthracene (DMBA). It was reported that the DMBA-induced rat mammary tumor cell line produced two angiogenic factors, rAF-1 and rAF-2, and these two factors did not have a stimulatory effect on vascular endothelial cell proliferation.
32) The angiogenic factors such as vascular endothelial growth factor (VEGF) and fibroblast growth factors (FGFs) have a stimula- tory effect on vascular endothelial cell proliferation. 33) So, rAF-1 and rAF-2 are considered to be different from VEGF and FGFs. FMPA inhibited the mouse sarcoma 180 cell-induced angiogenesis in the mouse dorsal air sac method 23) and it was reported that mouse S-180 sarcoma cells rapidly upregulated endothelial cell expression of basic FGF. 34) Therefore, it is considered that FMPA may inhibit the angiogenesis induced by angiogenic factors such as rAF-1, rAF-2 and basic FGF. Further investigations are necessary to elucidate the mechanism of anti-angiogenic action of FMPA.
It is well known that anti-angiogenic steroids inhibit angiogenesis. 32, [35] [36] [37] Anecortave acetate exhibited the anti-angiogenic activity in both a rat model of retinopathy of prematurity and an intraocular tumor model. 38, 39) It has also been reported that anecortave acetate is clinically efficacious for improving vision in patients with exudative AMD by the posterior juxtascleral administration (15 mg).
14) It has been reported that betamethasone shows anti-angiogenic activities in some experimental studies. [18] [19] [20] In this study, we evaluated the effects of anecortave acetate and betamethasone, anti-angiogenic steroids, on laser-induced CNV in rats as positive controls. Anecortave acetate and betamethasone significantly inhibited the incidence of CNV formation as compared with the vehicle injected group at doses of 1000 mg/eye and 100 mg/eye, respectively. There was no statistical difference between the incidences of CNV in FMPA injected group (1000 mg/eye) and that in anecortave acetate injected group (1000 mg/eye), but the incidences of CNV in FMPA injected group (1000 mg/eye) was somewhat lower than that in anecortave acetate injected group (1000 mg/eye). Therefore, it is suggested that FMPA may be effective for exudative AMD equal to anecortave acetate. While, it is suggested that betamethasone might have caused systemic side effects because changes of body weight in the betamethasone-injected group were significantly inhibited compared with the vehicle-treated group. In contrast, FMPA showed the inhibitory effect on changes of body weight only at the highest dose (3000 mg/eye) in this study. Although FMPA showed the inhibitory effect on the incidence of CNV formation at doses of 300 and 1000 mg/eye, FMPA did not affect the body weight gains at these doses. Therefore, FMPA might be effective for the laser-induced CNV model in rats without producing systemic side effects at doses of 300 and 1000 mg/eye. Further studies are needed to determine the appropriate dose of FMPA.
In order to confirm whether or not FMPA had retinal toxicity, examination of the retinal function was performed by ERG, because the ERG values obtained from BN rats show no individual difference. 40) In this study, FMPA did not affect the retinal function by ERG, so subconjunctival injection of FMPA seemed to be safe for the treatment of AMD.
In conclusion, it was demonstrated that subconjunctival injection of FMPA inhibits the laser-induced CNV formation in rats. It is suggested that FMPA may be useful for exudative AMD.
